Lirentelimab (Anti-Siglec-8) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). It can be used for the research of eosinophilic gastritis and duodenitis. MW :150 KD.